Tekmira files IND with FDA

Tekmira Pharmaceuticals (TSX:TKM) has filed an investigational new drug application seeking approval from the FDA to begin a Phase 1 clinical trial to evaluate PLK1 SNALP as a treatment for solid tumour cancers. “This is another important milestone for Tekmira as we continue to both advance our own pipeline of RNA-interference drug candidates and support our [...]

YM begins Phase 2 brain metastases trial for nimotuzumab

YM BioSciences (AMEX:YMI; TSX:YM) enrolled its first U.S. patient at the Florida Cancer Institute in a Phase 2 clinical trial evaluating its nimotuzumab drug in patients with brain metastases from NSCLC . Last year, the U.S. Department of the Treasury’s Office of Foreign Assets Control lifted the limitation on the development of nimotuzumab in the [...]